Hepatosteatosis Patients with Pseudocontrast Sign in COVID-19: Relationships with Disease Severity and Survival Times

Introduction: The aim of the study was to investigate associations between hepatosteatosis (HS) with computed tomography severity score (CT-SS) and survival of coronavirus disease 2019 (COVID-19) patients attending the hospital. Methods: Our study was a retrospective analysis of 435 reverse transcription polymerase-chain reaction-positive COVID-19 patients (aged ≥ 18 years) who attended our hospital between September and December 2021. The patient’s chest CT parenchymal findings and CT-SSs were reported. For quantitative analysis, HS was defined if hep-atic-to-splenic attenuation ratio (CTL/S)<1. In very fatty livers, we defined the hyperdense appearance of vascular structures compared to liver parenchyma as “pseudocontrast sign (PCS).” We divided patients into three groups based on the hepatic attenuation comparison of vascular attenuation. Group 1: no HS, Group 2: HS without PCS, and Group 3: HS with PCS. Results: 210/435 (48.3%) patients were included in Group 1, 184/435 (42.3%) in Group 2, and 41/435 (9.4%) in Group 3. The Mean CTL/S of Group 3 was 0.56±0.14, which was significantly lower than the other two groups (p<0.001). There was a very significant (p<0.001) negative correlation between CT-SS and CTL/S. There was no significant difference between HS groups with intensive care unit (ICU) admission (p=0.27) and mortality (p=0.64). In multivariate Cox regression analysis, HS with PCS was an 11-fold (p<0.001) risk factor for shortening the time from hospital admission to death and 3-fold (p=0.035) for shortening the time from ICU admission to death. Discussion and Conclusion: In our study, HS with the PCS was significantly associated with CT-SS but not with overall mortality. Consequently, this sign may be an independent indicator of shorter survival times among patients who died. However, multicenter studies are needed in a large patient population.